Sharron Gargosky - Prima Biomed Chief Technical Officer

Executive

Dr. Sharron Gargosky is Chief Technical Officer of Prima Biomed Ltd. and was with Prima BioMed since August 2010. Dr. Gargosky has over 19 years experience in the biotechnology and pharmaceutical industries and has worked in senior positions in organizations that have successfully received FDA approval for orphan drugs. She is responsible for managing the clinical team working on the CVac immunotherapy cancer vaccine. Prior to joining Prima BioMed Dr. Gargosky was a member of ILMU consulting LLC where she provided project management and operational expertise on pharmaceutical drug and biologic development from early research to Phase IV Trials and the FDA approval process. Dr. Gargosky has also previously held the positions of Chief Scientific Officer at Pulse Health LLC in Portland in the USA and Chief Scientific Officer and Senior Vice President of Corporationrationrate Development at Hyperion Therapeutics Inc. in San Francisco. At Ucyclyd Pharma she managed the approval of orphan drug products and the development of the NCE and within Medics Pharmaceuticals the successful BLA submission and approval for Reloxin. As Vice President of Business Development for Diagnostic System Laboratories she was responsible for business expansion through evaluation and implementation of new growth opportunities and patent portfolio management since 2012.
Age 50
Tenure 12 years
Professional MarksPh.D
Phone61 2 8315 7003
Webhttp://www.primabiomed.com.au
Gargosky has a Postdoctoral Fellowship in Pediatric Endocrinology from Stanford University in California, a Ph.D in biochemistry from University of Adelaide in Australia, First Class Honors in Biochemistry from University of Adelaide, and a BS, Biochemistry, Microbiology, Immunology & Virology from University of Adelaide.

Prima Biomed Management Efficiency

The company has return on total asset (ROA) of (15.25) % which means that it has lost $15.25 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (30.29) %, meaning that it created substantial loss on money invested by shareholders. Prima Biomed's management efficiency ratios could be used to measure how well Prima Biomed manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 4.6 M in liabilities with Debt to Equity (D/E) ratio of 21.7, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Prima Biomed has a current ratio of 5.93, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Prima Biomed until it has trouble settling it off, either with new capital or with free cash flow. So, Prima Biomed's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Prima Biomed sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Prima to invest in growth at high rates of return. When we think about Prima Biomed's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Debra SPHRMustang Bio
N/A
Christopher GuldenSL Green Realty
N/A
Steven DurelsSL Green Realty
65
Josephine HellschliengerAbcellera BiologicsInc
N/A
Kathleen BAAbcellera BiologicsInc
N/A
Richard MDCalliditas Therapeutics
60
David FerraroCalliditas Therapeutics
N/A
Richard MSMustang Bio
N/A
Robyn MAAcumen Pharmaceuticals
N/A
CGA CPAAbcellera BiologicsInc
N/A
Ping RawsonDyadic International
43
Esq JDAbcellera BiologicsInc
54
Richard CurrentiSL Green Realty
N/A
Maggie HuiSL Green Realty
60
Neil MBAAbcellera BiologicsInc
54
JD EsqAcumen Pharmaceuticals
53
Doug BADyadic International
N/A
Bruce MDMustang Bio
N/A
Teona JohnsonCalliditas Therapeutics
N/A
Murray McCutcheonAbcellera BiologicsInc
N/A
Peter CarneyMustang Bio
37
Prima BioMed Ltd. engages in the research, development, and commercialization of medical biotechnology solutions in Australia. Prima Biomed (PBMD) is traded on NASDAQ Exchange in USA and employs 31 people.

Management Performance

Prima Biomed Leadership Team

Elected by the shareholders, the Prima Biomed's board of directors comprises two types of representatives: Prima Biomed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Prima. The board's role is to monitor Prima Biomed's management team and ensure that shareholders' interests are well served. Prima Biomed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Prima Biomed's outside directors are responsible for providing unbiased perspectives on the board's policies.
Pete Meyers, Non-Executive Director
Russell Howard, Non-Executive Director
Larisa Chisholm, Director of Industry Liaison and Devel. and Director of Intellectual Property
Tom Bloomfield, Joint Company Secretary
YueLing Wong, Non-Executive Deputy Chairman of the Board
Frederic Triebel, Chief Scientific Officer & Chief Medical Officer
Deanne Miller, General Counsel, Company Secretary
Sharron Gargosky, Chief Technical Officer
Grant Chamberlain, Non-Executive Director
Lucy Turnbull, Non-Executive Chairman of the Board
Marc Voigt, CEO, CFO, Chief Bus. Officer, Executive Director, Member of Audit and Risk Committee and Member of Remuneration Committee
Matthew Gregorowski, IR Contact Officer

Prima Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Prima Biomed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Prima Biomed using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

Other Consideration for investing in Prima Stock

If you are still planning to invest in Prima Biomed check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Prima Biomed's history and understand the potential risks before investing.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Global Correlations
Find global opportunities by holding instruments from different markets